BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34851506)

  • 1. Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.
    Park SC; Lee JM
    Genes Genomics; 2022 Mar; 44(3):369-377. PubMed ID: 34851506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
    Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
    Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
    J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
    Hung SY; Lin HH; Yeh KT; Chang JG
    Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA polymerase II phosphorylation at serine 2 and histone H3 tri-methylation at lysine 36 are key steps for thyroid hormone receptor β gene activation by thyroid hormone in Rana catesbeiana tadpole liver.
    Mochizuki K; Ishihara A; Goda T; Yamauchi K
    Biochem Biophys Res Commun; 2012 Jan; 417(3):1069-73. PubMed ID: 22226961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by
    Huang B; Huang M; Li Q
    Technol Cancer Res Treat; 2019; 18():1533033819879905. PubMed ID: 31757187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
    Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
    Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
    Francalanci P; Giovannoni I; De Stefanis C; Romito I; Grimaldi C; Castellano A; D'Oria V; Alaggio R; Alisi A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal.
    Zhu P; Wang Y; Huang G; Ye B; Liu B; Wu J; Du Y; He L; Fan Z
    Nat Struct Mol Biol; 2016 Jul; 23(7):631-9. PubMed ID: 27239797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma.
    Wei L; Liu Q; Huang Y; Liu Z; Zhao R; Li B; Zhang J; Sun C; Gao B; Ding X; Yu X; He J; Sun A; Qin Y
    Int J Biochem Cell Biol; 2020 Mar; 120():105685. PubMed ID: 31917284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipocyte Thyroid Hormone β Receptor-Mediated Hormone Action Fine-tunes Intracellular Glucose and Lipid Metabolism and Systemic Homeostasis.
    Ma Y; Shen S; Yan Y; Zhang S; Liu S; Tang Z; Yu J; Ma M; Niu Z; Li Z; Wu Y; Zhao L; Lu Z; Wei C; Zhang WJ; Xue Y; Zhai Q; Li Y; Hu C; Jiang J; Li Y; Ying H
    Diabetes; 2023 May; 72(5):562-574. PubMed ID: 36724137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific histone lysine 4 methylation patterns define TR-binding capacity and differentiate direct T3 responses.
    Bilesimo P; Jolivet P; Alfama G; Buisine N; Le Mevel S; Havis E; Demeneix BA; Sachs LM
    Mol Endocrinol; 2011 Feb; 25(2):225-37. PubMed ID: 21239616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma.
    Xu F; Li CH; Wong CH; Chen GG; Lai PBS; Shao S; Chan SL; Chen Y
    Cancer Res; 2019 Apr; 79(7):1305-1317. PubMed ID: 30718359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.